Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations

Optimizing Targeted Therapy for HER2-Positive Advanced Breast

Cancer: First-line Considerations

Program Goals

Serum Tumor Markers for Monitoring Disease Progression in Patients With Advanced Breast Cancer

Case 1: 48-Year-Old Woman Diagnosed With Recurrent ER/PR-Positive, HER2-Positive Breast

Cancer (cont)

Case 1: 48-Year-Old Woman Diagnosed With Recurrent ER/PR-Positive, HER2-Positive Breast

Cancer (cont)

Tamoxifen vs Aromatase Inhibition in Hormone Receptor-Positive MBC

Case 2: 65-Year-Old Women Diagnosed With Recurrent ER/PR-Negative, HER2-Positive Breast

Cancer

Case 2: 65-year-old Women Diagnosed With Recurrent ER/PR-Negative, HER2-Positive Breast Cancer (cont)

Phase 3 CLEOPATRA Trial: Safety

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)